Evidence map›Paper›PMID 33476465›Full record

ArticleClinical and translational science2021

Critical need for pharmacologic treatment options in NAFLD: A pediatric perspective.

Chance S Friesen, Sherwin S Chan, Jonathan B Wagner, Chelsea Hosey-Cojocari, Iván L Csanaky, Valentina Shakhnovich

Open access · goldAbstract read
In one paragraph

Article in Clinical and translational science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Chance S FriesenSchool of Medicine, University of Kansas, Kansas City, Missouri, USA.
Sherwin S ChanChildren's Mercy Kansas City, Kansas City, Missouri, USA.
Jonathan B WagnerChildren's Mercy Kansas City, Kansas City, Missouri, USA.
Chelsea Hosey-CojocariChildren's Mercy Kansas City, Kansas City, Missouri, USA.
Iván L CsanakyChildren's Mercy Kansas City, Kansas City, Missouri, USA.
Valentina ShakhnovichChildren's Mercy Kansas City, Kansas City, Missouri, USA.
University of Missouri–Kansas City · USChildren's Mercy Hospital · USUniversity of Kansas · US

Funding

RADx-UP: Improving the Response of Local Urban and Rural Communities to Disparities in Covid-19 TestingUL1TR002366 · NCATS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Mario Castro, JAMES STEVEN LEEDER · 2017 to 2026
$44.3M
Effect of Obesity on Pantoprazole Pharmacokinetics and Pharmacodynamics in ChildrenK23DK115827 · NIDDK · CHILDREN'S MERCY HOSP (KANSAS CITY, MO) · PI SHAKHNOVICH, VALENTINA · 2020 to 2023
$756k
NCATS NIH HHS UL1 TR002366NIDDK NIH HHS K23 DK115827
6 · The paper itself

Abstract

Nonalcoholic fatty liver disease (NAFLD) affects up to 70% of children with obesity and has become the number one etiology for liver transplant in the United States. Early, effective intervention is critical to prevent disease progression into adulthood. Yet, it is seldom achieved through lifestyle modification alone. Thus, children must be included in NAFLD pharmacology trials, which, to date, continue to focus primarily on adult populations. This commentary serves as a call to action.

Indexed as

Patient SelectionAdultAge FactorsChildClinical Trials as TopicDisease ProgressionEnd Stage Liver DiseaseHumansNon-alcoholic Fatty Liver DiseasePediatric Obesity

Identifiers

PMID33476465
PMCPMC8212707
OpenAlexW3122283570

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.